Enterprise Value

309.7M

Cash

58.66M

Avg Qtr Burn

-13.05M

Short % of Float

4.73%

Insider Ownership

1.44%

Institutional Own.

69.91%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

TAVALISSE® (fostamatinib disodium hexahydrate) Details
Adult Chronic Immune Thrombocytopenia (ITP)

Approved

Quarterly sales

REZLIDHIA (olutasidenib) Details
Cancer, Acute myeloid leukemia

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Data readout

R552 Details
Rheumatoid arthritis, Autoimmune disease

Phase 2a

Data readout

R289 Details
Lower-risk myeloid dysplastic syndrome

Phase 1b

Data readout

Failed

Discontinued